Novo Nordisk is launching an unsolicited bid to acquire obesity-drug developer Metsera. The Danish pharmaceutical company, known for blockbusters like Ozempic and Wegovy, offers $56.50 per share in cash with the potential for another $21.25 if certain milestones are reached. This deal could potentially top Pfizer’s previous offer of the same value. A legal battle may ensue as Metsera had accepted Pfizer’s proposal last month, leaving both companies poised to clash over the biotech firm.
Source: https://www.wsj.com/health/pharma/novo-nordisk-moves-to-outbid-pfizer-with-up-to-9-billion-offer-for-obesity-drug-developer-metsera-42420b97